HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Calverley, P. M. A. Search for Related Content PubMed PubMed Citation Articles by Calverley, P. M. A.

Reducing the Frequency and Severity of Exacerbations of Chronic Obstructive Pulmonary Disease

Department of Medicine, University Hospital Aintree, Clinical Sciences Centre, Liverpool, United Kingdom

Correspondence and requests for reprints should be addressed to Peter M. A. Calverley, Department of Medicine, University Hospital Aintree, Clinical Sciences Centre, Longmoor Lane, Liverpool L9 7AL, UK. E-mail: pmacal{at}liverpool.ac.uk

Exacerbations contribute significantly to impaired health status in chronic obstructive pulmonary disease (COPD), but current therapy can prevent these episodes. Immunization against, for example, influenza offers specific prophylaxis for a minority of episodes. Pulmonary rehabilitation reduces hospital attendance, but its effect wanes. Inhaled bronchodilators such as tiotropium produce similar reductions in exacerbation frequency. Database studies show an association between prescription of inhaled corticosteroids and reduced hospitalization in the older population, a finding confirmed by randomized trials in patients with an FEV₁ of less than 50% predicted. Three 1-year randomized clinical trials studied the effect of combining a long-acting ß-agonist with an inhaled corticosteroids. In these studies, exacerbation frequency was lower with therapy than placebo. Combination therapy had a similar effect to its monocomponents in the trial of inhaled steroids and long-acting ß agonists study using salmeterol and fluticasone. However, when patients with more severe COPD (an FEV₁ of less than 36% predicted) were studied using a combination of budesonide and formoterol, a clear improvement was seen in the overall exacerbation rate compared with the ß-agonist alone. In addition, the time to first exacerbation was increased compared with either drug alone. Health status changes mirrored these effects. In summary, combination therapy can effectively prevent exacerbations in patients with more advanced COPD.

Key Words: chronic obstructive pulmonary disease • exacerbation • therapy • combination therapy • corticosteroid • bronchodilator

This article has been cited by other articles:

				A. F. Gelb, C. F. Taylor, P. A. McClean, C. M. Shinar, M. T. Rodrigues, C. A. Gutierrez, K. R. Chapman, and N. Zamel Tiotropium and Simplified Detection of Dynamic Hyperinflation Chest, March 1, 2007; 131(3): 690 - 695. [Abstract] [Full Text] [PDF]

				S. Jarvis, P. W. Ind, and R. J. Shiner Inhaled therapy in elderly COPD patients; time for re-evaluation? Age Ageing, March 1, 2007; 36(2): 213 - 218. [Abstract] [Full Text] [PDF]

				D. E. Niewoehner, Y. Lokhnygina, K. Rice, W. G. Kuschner, A. Sharafkhaneh, G. A. Sarosi, P. Krumpe, K. Pieper, and S. Kesten Risk Indexes for Exacerbations and Hospitalizations Due to COPD Chest, January 1, 2007; 131(1): 20 - 28. [Abstract] [Full Text] [PDF]

				R. Buhl and S. G. Farmer Current and Future Pharmacologic Therapy of Exacerbations in Chronic Obstructive Pulmonary Disease and Asthma Proceedings of the ATS, April 1, 2004; 1(2): 136 - 142. [Abstract] [Full Text] [PDF]